Feature | August 28, 2014

University of Michigan First in Nation to Implant Device for Tricuspid Valve Replacement

Heart team implants Edwards Sapien valve for landmark transcatheter tricuspid valve replacement

The Edwards Lifesciences Sapien valve used for transcatheter tricuspid valve replacement at the University of Michigan.

Steven F. Bolling, M.D., cardiac surgeon at the University of Michigan Frankel Cardiovascular Center, lead a mutidisciplinary team in successful transcatheter tricuspid valve replacement.

August 28, 2014 — The University of Michigan Frankel Cardiovascular Center is the first heart center in the nation to perform percutaneous implantation of the Edwards Sapien valve to replace a patient’s tricuspid valve. Cardiac surgeon Steven Bolling, M.D., interventional cardiologist Stanley Chetcuti, M.D., interventional cardiologist Daniel Menees, M.D., and cardiac surgeon Matthew Romano, M.D., successfully completed the procedure Aug. 11.

Because of the less invasive approach, the 47-year-old patient was discharged after only a two-day hospital stay. “Minimally invasive surgery for tricuspid valve replacement is a new solution for the dilemma of treating valve disease in which repeat surgeries are often needed but problematic,” said Bolling, director of the U-M Mitral Valve Clinic. “This was a rewarding result for all of us.”

Compared to the rapid expansion of transcatheter aortic valve replacement (TAVR) procedures, transcatheter tricuspid valve-in-valve implantation is just beginning.

The U-M cardiac team replaced the patient’s diseased heart valve to improve blood flow on the right side of the heart. Tricuspid valve stenosis had caused the valve to narrow. Adding to the complexity, her heart valve had been replaced before using animal tissue.

For more information: www.umcvc.org

Related Content

Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init